(Bloomberg) — The trade was simple — and worked until it didn’t. Wrap crypto in a stock ticker. Call it innovation. Ride the wave. This week, with the crypto complex buckling alongside a tech-stock selloff, that wave is crashing. And some of its biggest promoters — including President Donald Trump ally David Bailey, Ethereum bull Tom Lee and Bitcoin evangelist Michael Saylor — must now deal with the fallout. Bitcoin’s slide below $100,000 for the first time since June has ratcheted up pressure on shares ...

Core Viewpoint - The US government is investigating JPMorgan Chase over allegations of "debanking" customers with conservative political ties, following claims made by former President Trump [1][10]. Group 1: Investigation and Responses - JPMorgan Chase is responding to requests from government authorities regarding its policies and processes related to customer service [1]. - The investigation is linked to Trump's executive order from August, which called for scrutiny of banking policies that may lead to politicized debanking [1][9]. - Bank of America has also indicated it is responding to demands for "fair access to banking" in light of the executive order [4]. Group 2: Allegations and Claims - Trump accused JPMorgan and Bank of America of rejecting over $1 million of his deposits for political reasons after leaving office in 2021 [2]. - Melania Trump claimed her banking account was closed shortly after the January 6 riots, suggesting a pattern of debanking against conservatives [3]. - Former Republican Kansas Governor Sam Brownback alleged that JPMorgan closed his account due to his conservative views, a claim the bank denied [8]. Group 3: Regulatory Context - Trump's executive order emphasizes the concept of "reputation risk," which may lead banks to reject clients based on political affiliations [9]. - The order highlights the negative impacts of debanking on individuals, including financial harm and damage to reputations [9]. - Banks that engage in debanking practices may face fines or penalties from regulators as a result of the investigation [9].

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Welcome to Yahoo Finance's flagship show, The Morning Brief. I'm Ally Canal. Let's get to the three things you need to know today.First up, US stocks bouncing off session lows. Futures slightly higher after a sharp tech sell-off that wiped about 500 billion in market value from chip stocks in the socks index as investors grow more cautious about lofty valuations. Crypto is also taking a hit.Bitcoin dropping below $100,000 per token for the first time since June. The sell-off has somewhat eased, but it's sti ...

Wall Street excels at creating catch phrases. The latest one is the "debasement trade. ...

Accessibility StatementSkip Navigation Paige Bueckers, Bryson DeChambeau, CeeDee Lamb and Draymond Green come face-to-face with Santa to secure their spot on this year's nice roster PITTSBURGH, Nov. 5, 2025 /PRNewswire/ -- This holiday season, DICK'S Sporting Goods (NYSE: DKS) is partnering with some of the biggest names in sports to launch Santa's Scouting Report, a campaign that puts a playful, sports-themed spin on the classic naughty or nice list. Santa's Scouting Report Santa's Scouting Report - Hero I ...

Core Insights - Pfizer and Novo Nordisk are engaged in a competitive bidding war for the obesity biotech Metsera, with both companies increasing their offers as of Monday [3][4] - Metsera has indicated that Novo Nordisk's latest bid of up to $10 billion is superior to Pfizer's revised offer of approximately $8.1 billion [9][10] Group 1: Bidding War Timeline - Pfizer initially proposed to acquire Metsera for $4.9 billion, potentially rising to $7.3 billion with future payments, aiming to enter the obesity market after previous setbacks [5] - Novo Nordisk launched a competing bid valuing Metsera at around $6 billion, or up to $9 billion, prompting Pfizer to renegotiate its offer within a four-business-day deadline [6] - Following Novo Nordisk's bid, Pfizer filed lawsuits against both Novo Nordisk and Metsera, seeking to block the termination of its merger agreement [7][16] Group 2: Market Context and Implications - Metsera, founded in 2022, has a pipeline of oral and injectable treatments, including a GLP-1 drug and a monthly amylin treatment, which could be less frequent than existing weekly injections [11] - The acquisition of Metsera is crucial for Pfizer to penetrate the lucrative obesity market, especially after facing challenges with its own weight loss candidates [12] - Novo Nordisk, a pioneer in the weight loss drug market, is under pressure to regain market share lost to competitors like Eli Lilly and is facing new entrants such as Amgen and Roche [13][14] Group 3: Legal and Regulatory Aspects - Pfizer's lawsuits argue that Novo Nordisk's acquisition of Metsera would reinforce its dominant position in the obesity market by eliminating a potential competitor [16] - Pfizer's first lawsuit seeks to prevent Metsera from terminating its existing merger deal, claiming that Novo Nordisk's offer is not likely to be completed due to regulatory risks [17] - A Delaware judge has scheduled a hearing to review the bidding process, indicating ongoing legal complexities in the acquisition battle [18]

Honda Motor said on Thursday it is developing a platform centred on mid-size hybrid cars and a hybrid system for large vehicles, as the Japanese automaker seeks to boost competitiveness amid a slower ... ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Sempra reported quarterly earnings of $1.11 per share, exceeding the Zacks Consensus Estimate of $0.93 per share, and showing an increase from $0.89 per share a year ago, resulting in an earnings surprise of +19.35% [1] - The company generated revenues of $3.15 billion for the quarter ended September 2025, which was 2.2% below the Zacks Consensus Estimate, but up from $2.78 billion year-over-year [2] - Sempra's stock has increased by approximately 5.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.28, with expected revenues of $3.71 billion, and for the current fiscal year, the EPS estimate is $4.53 on revenues of $13.73 billion [7] - The estimate revisions trend for Sempra was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Utility - Gas Distribution industry, to which Sempra belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Spire, is expected to report a quarterly loss of $0.46 per share, with revenues projected at $307.96 million, reflecting a year-over-year increase of 4.8% [9][10]